NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » TOP China Pharmas » 3SBIO (Shenyang Sunshine)  1  2  » 
found files: 21
3SBIO (Shenyang Sunshine) »03/05/2007 [Company watch]
3SBio Inc. Announces First Quarter 2007 Results

this company is getting a lot of attention - sells products similar to Amgen but without the side effects. Very large growth potential...   more»


3SBIO (Shenyang Sunshine) »15/08/2007 [Company watch]
3SBio Hits Q2 Targets, Reports 50% Increase in Revenue

3SBio (SSRX), the Shenyang biotech that made its U.S. IPO in February, released its second quarter financial report, showing the company greatly increased both revenues and earnings....   more»


3SBIO (Shenyang Sunshine) »03/11/2007 [Company watch]
3SBio takes lion share in China's EPO market

Recombinant human erythropoietin (EPO) injection product Epiao of Shenyang Sunshine Pharmaceutical Co., Ltd. (3Sbio, SSRX.NASDAQ) has seen brisk sales and now takes a market share of 37 percent in China....   more»


3SBIO (Shenyang Sunshine) »15/11/2007 [Company watch]
3SBio Inc. Q3 net far outgrows revenue

Chinese biotech company 3SBio Inc. ( SSRX.NASDAQ) posted 57.3 percent net revenue rise in the 3rd quarter from the same period of 2006 to 7.5 million U.S. dollars, according to its latest financial report issued on Tuesday....   more»


3SBIO (Shenyang Sunshine) »28/01/2008 [Company watch]
3Sbio appoints Kevin Sow Peng Teo CFO

Chinese biotech company 3Sbio has appointed of Kevin Teo as the Chief Financial Officer. A company release said Teo would be replacing Clara Mak, who is resigning for personal reasons. To assist with the transition, Ms. Mak will stay on with the Company until February 29, 2008. Dr. Jing Lou, CEO of 3SBio, commented, "I am pleased to welcome Kevin Teo to 3SBio's senior management team. After a focused search, Kevin emerged as the clear choice to fill the role of Chief Financial Officer at 3SBio, as he brings with him a wealth of experience in finance and accounting with some of the leading companies in the region. I have full confidence in Kevin's ability to transition smoothly into the role of the CFO of 3SBio, and we look forward to his contributions and leadership as we continue to build 3SBio into the leading biotech company in China. Clara Mak, who has been an integral part of the team, has led 3SBio through the IPO process and on to continued growth as a public company. Her financial leadership has also been instrumental in helping the company successfully position itself for continued solid performance and she will be missed. We wish her the best in her future endeavors." Teo has over two decades experience working with various companies in a variety of positions. He was the Group Business Controller at East Asia Power (Xiamen), where he oversaw and managed finance and accounting teams located in Hong Kong, Singapore, Jakarta, Xiamen, Nanjing and Beijing. Before East Asia Power, Teo held senior roles at Huawei Technologies Co. Ltd. (Shenzhen), Siemens Malaysia Sdn. Bhd., Siemens Cerberus Sdn. Bhd., Wetlands International - Asia Pacific, Chua Song Seng, and Anuarul Azizan Chew...   more»


3SBIO (Shenyang Sunshine) »19/03/2008
3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer

3SBio Inc. (''3SBio'' or the ''Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio....   more»


3SBIO (Shenyang Sunshine) »23/03/2008 [Company watch]
3S Bio announce new appointment

3SBio Inc. (''3SBio'' or the ''Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Dr. David Chen to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Dr. Chen most recently held the position of Vice President of Business Development at 3SBio. Since joining 3SBio in June 2007, Dr. Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr. Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China....   more»


3SBIO (Shenyang Sunshine) »19/05/2008 [Company watch]
3SBIO reports Higher first qtr revenues

In the first quarter of 2008, 3SBio saw its sales jump 57% to 55.5 million RMB ($7.9 million). Gross profit climbed 56% to 50.6 million RMB ($7.2 million). However, net income did not keep pace, rising a much smaller 22% to 14.2 million RMB ($2 million). Apparently, 3SBio spent a lot of money to create the increase in revenues, because the cause for the shortfall in net income was higher spending in the sales, marketing and distribution category. This item climbed 65% to 25.6 million RMB (US$3.7 million), a figure that represents 46% of the company’s revenues. In the battle between promoting revenues or profits, 3SBio came down heavily on the side of revenues, and net income suffered as a result. 3SBio has two products that produce the preponderance of its sales: • injectable recombinant human erythropoietin [EPO] products, collectively branded as EPIAO, produced 35.5 million RMB ($5.1 million) in revenue, a rise of 42%; and • protein-based therapeutic recombinant human thrombopoietin [TPO] products, marketed as TPIAO, produced 15.4 million RMB ($2.2 million) in sales, an increase of 104%. Together, these two product lines sold $7.3 million of the total $7.9 million that 3SBio reported on its top line. Net income per ADS was recorded as 13 cents for Q1. Each ADS represents seven ordinary shares....   more»


3SBIO (Shenyang Sunshine) »28/05/2008 [Company watch]
3SBio to Commercialize Iron Deficiency Agent in China

3SBio, Inc. has signed a development-commercialization deal with AMAG Pharmaceuticals, Inc. (NSDQ: AMAG) to obtain SFDA approval and then market ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease [CKD] patients. 3SBio’s flagship drugs, EPIAO, an injectable recombinant human erythropoietin, and TPIAO, a protein-based therapeutic recombinant human thrombopoietin, are sold largely to dialysis patients with chronic kidney disease. 3SBio paid $1 million upfront and will make milestone payments as ferumoxytol achieves regulatory goals for chronic kidney disease and other indications. AMAG will also receive tiered, double-digit royalties, up to 25%, based on sales of ferumoxytol. 3SBio will assume complete financial responsibility for the approval process of ferumoxytol in China, which will be administered by a joint 3SBio-AMAG steering committee. Under the agreement, 3SBio will have rights to the drug for 13 years. If minimum levels of sales are met, the agreement will be automatically renewed. AMAG will manufacture ferumoxytol and sell it to 3SBio at a set supply price. Ferumoxytol has completed its clinical trials in the US, and AMAG submitted its request for FDA approval of the drug in December 2007. According to AMAG, there are 12 million Stage 3 and 4 CKD patients and over 91,000 patients on dialysis in China. AMAG used a proprietary nanoparticle technology to develop the drug. 3SBio is based in Shenyang and AMAG is headquartered in Cambridge, MA....   more»


3SBIO (Shenyang Sunshine) »04/06/2008 [Company watch]
AMAG Pharma, 3SBio Partner to Develop Ferumoxytol Market in China

U.S. drug company AMAG Pharmaceuticals Inc. (AMAG) announced Tuesday that it has signed an agreement with 3SBio Inc. (SSRX) to develop the market in China for ferumoxytol, an iron deficiency anemia drug produced by AMAG. The product, ferumoxytol, is an intravenous iron replacement drug for treating iron deficiency anemia among chronic kidney disease [CKD] patients. It will enter the Chinese pharmaceutical market through the cooperation between AMAG Pharma and 3SBio. AMAG Pharma chose 3SBio as its partner to develop the product in China due to 3SBio's leading position in the nephrology therapeutic market, its strong sales network across the country and its rich marketing experience, according to the announcement. According to the terms of the agreement, 3SBio is AMAG Pharma's exclusive partner in China for developing ferumoxytol in the country, including promoting the use of the product in clinical trials, getting approval from the State Food and Drug Administration, as well as expanding the product's market share. AMAG Pharma and 3SBio will set up a joint steering committee, made up by an equal number of representatives of each company, to guide the development of the product in China. The agreement will last for 13 years and will be renewed depending on sales performance. In addition, AMAG Pharma will receive an advance payment of $1 million from 3SBio. 3SBio listed on the Nasdaq in February last year. It is mainly engaged in the manufacture, research and development and marketing of biopharmaceutical products in China...   more»


3SBIO (Shenyang Sunshine) »14/08/2008 [Company watch]
3SBio Reports Higher Q2 Revenues but Earnings Slip

3SBio reportedthat Q2 revenue increased 38% to 60 million RMB ($8.7 million), but net income actually declined 17% to 19 million RMB ($2.2 million). That number works out to earnings of 13 cents per ADS. The company took advantage of the higher sales numbers to raise its full-year 2008 revenue targets by about $4 million to a range of $34 million to $35 million. Net margin for Q2 of 2008 was 32.5% as compared to a sky-high 54.2% a year earlier. Revenue from 3SBio’s most important product, EPIAO, a recombinant human erythropoietin [EPO], rose 24% to $5.4 million. Sales of 3SBio’s newer product, TPIAO, a protein-based therapeutic recombinant human thrombopoietin [TPO] jumped 67% to $2.3 million. Despite the rise in revenues, operating income increased only 10.5% to $2.2 million. Meanwhile, operating expenses swelled by 54% to $5.7 million. The company blamed its increased costs on higher expenditures for sales, marketing and distribution as well as general and administrative expenses. In the conference call to investors, 3SBio said that the company is essentially creating a market among cancer patients for its TPIAO product. However, it acknowledged that this initiative has been going on for two and one-half years, which does not explain the sudden rise in costs. In any event, the company does feel the high costs of launching this product will eventually prove worthwhile. Stressing the positive, 3SBio reminded investors that it signed a partnership in Q2 with AMAG Pharma of Boston to develop and commercialize ferumoxytol in China. Ferumoxytol is a new-generation intravenous iron replacement therapeutic agent to treat iron deficiency anemia in chronic kidney disease ("CKD") patients. In the conference call, company officials said they thought the product might be able to complete the approval process and be launched in 2011. 3SBio said the company paid a $1 million upfront fee for the product. The company is also continuing its Phase III trial of high-dose EPIAO, which is administered once a week as opposed to three times per week for the normal version. 3SBio is in the process of analyzing the data from a Phase III trial of its kidney cancer drug, NuLeusin, a second generation IL-2. The company expects to file for approval of the drug in the second half of 2008. In the Phase III test, the drug causes an 11% partial response and one patient experienced a complete response. The Phase III trial for TPIAO as a treatment of idiopathic thrombocytopenic purpura [ITP] has completed enrollment. 3SBio expects to file for approval of TPIAO for this indication in Q4 of 2008. After the report was released, 3SBio dropped 3% or 34 cents to close at $10 per share. The company has a market capitalization of $217 million and a trailing 12 month P/E ratio of 17. With $115 million of cash on its books, 3SBio still has in its possession the majority of the capital it raised in its IPO. The company says its remains in the hunt for advantageous M&A deals, but any potential acquisition must be right in terms of price and/or synergies....   more»


3SBIO (Shenyang Sunshine) »26/09/2008 [Company watch]
3SBio Files for Approval of Anemia Treatment

3SBio Inc. (SSRX) has filed for SFDA approval of a high-dose, 36,000 IU formulation of EPIAO for the treatment of anemia resulting from chemotherapy. Unlike 3SBio’s other formulations of EPO, this one would be exclusive to the company. A 36,000 IU injection would be administered once every week, a significant advantage over the three-times per week administration of the more common 10,000 IU injections. In its clinical trial, the high-dose EPIAO performed at about the same levels as the low-dose formulation. In both cases, 70% of the patients experienced hemoglobin improvement of 1-2 g/dL from baseline. Safety and tolerability profiles were also similar. A low grade fever, which disappeared in time, was the major complaint. The Phase III trial enrolled 206 non-myeloid malignant tumor patients who were split into two groups: the once-per week high-dose 36,000 IU patients, and the three-times-per-week 10,000 IU patients. The trial also compared peak Hemoglobin value, nadir Hemoglobin value and the time required for the Hemoglobin value to increase more than 1 g/dL and 2 g/dL. There was no significant difference between the two groups on these secondary endpoints....   more»


3SBIO (Shenyang Sunshine) »31/10/2008 [Company watch]
3SBio Inc. Announces Preliminary Third Quarter 2008 Results

Lehman Brothers Bankrupcy affects 3 SBIO results. The Company\'s financial statements for the three months ended September 30, 2008 have not been finalized and are subject to completion of its normal quarter-end closing procedures. Therefore, the preliminary selected unaudited financial data set forth below may be subject to adjustment. As a consequence, actual results could differ materially from the expected results provided....   more»


3SBIO (Shenyang Sunshine) »28/11/2008 [Company watch]
3SBio Inc. Announces Third Quarter 2008 Results

3SBio Inc. a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the third quarter ended September 30, 2008....   more»


3SBIO (Shenyang Sunshine) »21/01/2009 [Company watch]
3SBIO Files for Approval on Three New Drugs

3SBio Inc. has filed for SFDA approval of a biologic drug, recombinant human thrombopoietin, known as TPIAO, as a treatment of idiopathic thrombocytopenic purpura (ITP)....   more»


3SBIO (Shenyang Sunshine) »10/02/2009 [Company watch]
3SBio appoints new Chief Financial Officer

3SBio, a biotechnology company focused on developing, manufacturing and marketing biopharmaceutical products primarily in China, has appointed Mr Bo Tan as Chief Financial Officer, effective February 1, 2009....   more»


3SBIO (Shenyang Sunshine) »14/04/2009 [Company watch]
Test 1234

test1234...   more»


3SBIO (Shenyang Sunshine) »05/05/2009 [Company watch]
3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor

3SBio Inc. a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Ernst & Young Hua Ming as the Company\'s independent registered public accounting firm....   more»


TOP NEWS
3SBIO (Shenyang Sunshine)
»11/02/2010 [Company watch]
3SBio and Panacor Bioscience Enter Collaboration and License Agreement

3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil® for Hyperphosphatemia...   more»


3SBIO (Shenyang Sunshine) »15/03/2010 [Company watch]
3SBio Announces Changes to its Board of Directors

3SBio Inc.(Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced changes to its board of directors (the \"Board\")....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.